Predicting MEK inhibitor response in lung cancer: A proper signature is required Journal Article
| Authors: | Xue, Y.; Lito, P. |
| Article Title: | Predicting MEK inhibitor response in lung cancer: A proper signature is required |
| Abstract: | The ERK signaling pathway is one of the most commonly deregulated pathways in cancer. Assays that accurately measure ERK signaling output in clinical specimens would be extremely helpful not only in determining the pharmacodynamic effects of drug treatment but also in selecting those patients most likely to respond to therapy. © 2016 American Association for Cancer Research. |
| Journal Title: | Clinical Cancer Research |
| Volume: | 23 |
| Issue: | 6 |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2017-03-15 |
| Start Page: | 1365 |
| End Page: | 1367 |
| Language: | English |
| DOI: | 10.1158/1078-0432.ccr-16-2576 |
| PROVIDER: | scopus |
| PUBMED: | 27923842 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 May 2017 -- Source: Scopus |
